Incretin Mimetic

GLP-1 (Semaglutide)

FDA-approved with the strongest evidence base of any peptide therapy.

GLP1R signalingAMPK/mTORNF-κB inflammatory cascadeSREBP1 lipogenesis

94 A

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

Semaglutide is the most extensively studied peptide in modern metabolic medicine. FDA-approved for both type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), it has amassed the largest clinical trial evidence base of any GLP-1 receptor agonist. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events.

Mechanism of Action

Semaglutide binds to the GLP-1 receptor with high affinity, triggering a cascade of metabolic effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction via hypothalamic signaling. The downstream gene expression changes are well-characterized across multiple tissue types.

Evidence Base

Multiple Phase III RCTs (STEP, SUSTAIN, PIONEER, SELECT programs) involving tens of thousands of participants. FDA-approved across multiple indications. Published in NEJM, Lancet, and JAMA with extensive post-market surveillance data.

Gene Pathway Detail

GLP-1 receptor activation triggers well-mapped gene expression cascades: CREB-mediated transcription in pancreatic β-cells, NF-κB pathway suppression reducing inflammatory cytokine expression (IL-6, TNF-α, CRP), SREBP1/FASN downregulation in hepatic lipogenesis, and IRS1/AKT activation in insulin signaling. These pathways are directly monitorable via Biomeme's transcriptomic platform.

mRNA Monitoring Insight

Semaglutide produces the strongest and most reproducible mRNA monitoring signal of any peptide. Gene expression changes in inflammatory, metabolic, and insulin signaling pathways are detectable within weeks of treatment initiation — well before clinical weight or lab changes appear.

Safety Considerations

FDA-approved with extensive safety data. Most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea). Rare risks include pancreatitis and thyroid C-cell tumors (rodent signal). Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2.

FAQ

Why does semaglutide score so high?

Semaglutide has FDA approval across multiple indications, extensive RCT data, well-characterized gene pathways, and a strong safety profile — scoring highly across all four evidence dimensions.

Quick Facts

Category: Incretin Mimetic
Score: 94/100 (A)
Gene Pathways: 4 characterized

Sources

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.